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Introduction
Pharmacokinetic (PK) of drugs in critically ill patients
could vary from the general population. The pharmaco-
kinetics of linezolid presents a high variability. Patients
undergoing renal replacement therapy (RRT) could pre-
sent lower linezolid concentration than expected. The
pharmacokinetic/pharmacodynamic analysis (PK/ PD) is
a useful tool to optimize dosing regimens of antibiotic
therapy.
Objectives
To analyse the PK/PD profile of linezolid (LZ) in
patients with severe sepsis (SS) and RRT and to evaluate
the efficacy of linezolid for the treatment of infections
caused by gram-positive organisms.
Methods
Study developed in three tertiary hospitals in patients
with SS, RRT and treatment with LZ (600 mg q12 h).
8 each patient blood (prefilter and postfilter) and ultra-
filtrate samples were taken at the following times: pre-
dose, 0,5, 1, 2, 3, 6, 8-10 and 12 h. Concentrations of
LZ were determined by HPLC-UV. Demographic and
laboratory data were collected, considering impaired
liver function (ILF) as the elevation >2 times transami-
nase and/or elevated bilirubin and severe renal dysfunc-
tion (SRD) as the presence of CrCl < 15 ml/min. The
PK study was performed using WinNonlin program.
Calculation of the probability of successful treatment
(PST) for minimum inhibitory concentrations (MIC) of
2, defined as the probability that the ratio area under
the curve (AUC)/MIC is> 100 was performed. Quantita-
tive variables were expressed as mean and standard
deviation (SD), qualitative as percentages and were com-
pared using the Student t test and Chi square test
respectively. a significance level of 0,05.
Results
26 patients (73 % male) were included. The mean age was
63 years (SD 15), with an average weight of 78 kg
(SD 13). The mean dose of hemodiafiltration was 2,7 L/h
(SD 0,7). The PK parameters were: mean plasma clear-
ance (CL) of 8,9 L/h (SD 5,1), volume of distribution of
38,5 L (SD 10,1), elimination half-life of 3,8 h (SD 1,7)
and AUC0-24 h of 176,2 mg * h/L (SD 84,4). Patient with
SRD and ILF had higher AUC (246 vs 139), higher Cmin
(4,6 vs 1,9) and less CL (5,4 vs 10,7), p < 0,02. The contri-
bution of extracorporeal CL to the total CL was relevant
in the presence of SRD (44% vs 20%, p < 0.01). The
PK/PD target was only achieved in 38.4% of patients, 80%
with SRD and ILF. The following factors were identified
as predictors of treatment success: the presence of SRD
[RR 4,8 (1,7-13,9)], SRD and ILF [RR 12,8 (1,9-87,6)],
Cmin >2 mg/L [RR 2,3 (1,3-4)], and the presence of a
significant extracorporeal clearance (> 25%) [RR 5,3 (1,9-
14,8)], p < 0,01.
Conclusions
In our series, the current dose of linezolid allows achieving
the PK/PD target in patients with SRD and ILF. In the
absence of both dysfunctions, this aspect cannot be guar-
anteed. Although extracorporeal CL is significant in the1Osakidetza, Vitoria, Spain
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presence of SRD, this impresses not be a limiting factor in
achieving the PK/PD target.
Grant Acknowledgment
Pfizer sponsored this study.
Authors’ details
1Osakidetza, Vitoria, Spain. 2University of Basque Country, Vitoria, Spain.
3Doce de Octubre Hospital, Madrid, Spain. 4Joan XXIII Hospital, Tarragona,
Spain.
Published: 1 October 2015
doi:10.1186/2197-425X-3-S1-A880
Cite this article as: Barrasa González et al.: Pharmacokinetic/
pharmacodynamic analysis of linezolid in critically ill patients with
severe sepsis treated with renal replacement therapy. Intensive Care
Medicine Experimental 2015 3(Suppl 1):A880.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Barrasa González et al. Intensive Care Medicine Experimental 2015, 3(Suppl 1):A880
http://www.icm-experimental.com/content/3/S1/A880
Page 2 of 2
